BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 19234440)

  • 1. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
    Inamura K; Takeuchi K; Togashi Y; Hatano S; Ninomiya H; Motoi N; Mun MY; Sakao Y; Okumura S; Nakagawa K; Soda M; Choi YL; Mano H; Ishikawa Y
    Mod Pathol; 2009 Apr; 22(4):508-15. PubMed ID: 19234440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
    Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
    Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
    Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
    PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
    Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
    Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
    Murakami S; Yokose T; Saito H; Sakuma Y; Matsukuma S; Hasegawa C; Kondo T; Oshita F; Ito H; Tsuboi M; Nakayama H; Kameda Y; Noda K; Yamada K
    Lung Cancer; 2010 Sep; 69(3):361-4. PubMed ID: 20659620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
    Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
    Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
    Li T; Maus MK; Desai SJ; Beckett LA; Stephens C; Huang E; Hsiang J; Zeger G; Danenberg KD; Astrow SH; Gandara DR
    J Thorac Oncol; 2014 Jan; 9(1):18-25. PubMed ID: 24346090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
    J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
    Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
    Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
    Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
    Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
    PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.